WuXi Biologics Achieves AAA MSCI ESG Rating for the Second Consecutive Year
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings…
UNICEF and WHO Announce Completion of Second Round of Polio Campaign in Gaza Amid Ongoing Conflict
Second Round of Polio Vaccination Campaign in Gaza Completed Amid Ongoing Conflict: UNICEF and WHO The second round of the polio vaccination campaign in the Gaza Strip concluded yesterday, with…
Vaccine Doses Assigned to 9 African Countries Affected by Mpox Surge
The Access and Allocation Mechanism (AAM) for mpox has allocated an initial 899,000 vaccine doses to nine African countries severely impacted by the ongoing mpox outbreak. This distribution, made in…
Joint Statement from the WHO Director-General and the WHO Civil Society Task Force on Tuberculosis
The recently released Global Tuberculosis Report 2024 provides an updated overview of the challenges and progress in the global fight against tuberculosis (TB) during 2023. TB affected 10.8 million people…
Sarepta Therapeutics Reports Third Quarter 2024 Financial Results and Key Corporate Updates
Sarepta Therapeutics a leader in precision genetic medicine for rare diseases, has announced its financial results for the third quarter of 2024, showcasing strong revenue growth and significant progress in…
Legend Biotech to Present Landmark CARTITUDE-4 Trial Data on Minimal Residual Disease in Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, will showcase new findings from the Phase 3 CARTITUDE-4 trial on minimal residual disease (MRD) negativity rates in multiple…
Teva Reports Strong Q3 2024 Results, Boosted by Generics and Innovation; Raises 2024 Financial Outlook
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported its financial results for the third quarter ending September 30, 2024. Teva’s President and CEO, Richard Francis, commented, “We’ve achieved…
Ionis Unveils Phase 3 Trial Design for ION582 in Angelman Syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the design of a pivotal Phase 3 clinical trial for ION582, an investigational treatment for Angelman syndrome (AS), following successful alignment with the…
Revolution Medicines Announces Q3 2024 Financial Results and Provides Corporate Update
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and…
CRISPR Therapeutics Shares Business Update and Announces Q3 2024 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company developing transformative gene-based medicines for serious diseases, has released its financial results for Q3 ending September 30, 2024. “We are making strong progress…
Intra-Cellular Therapies Reports Positive Phase 3 Results for CAPLYTA in Preventing Schizophrenia Relapse
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, has announced positive results from Study 304, which evaluated the efficacy and safety…
BridgeBio Case Study on Portfolio Theory in Biomedical Innovation Published in JPM
BridgeBio Pharma, Inc. (Nasdaq: BBIO), an innovative biopharmaceutical company focused on treating genetic diseases, has announced the publication of a case study, “Applications of Portfolio Theory to Accelerating Biomedical Innovation,”…